Jonsson Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jonsson Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count).
Jonsson Comprehensive Cancer Center: 321 sponsored US clinical trials, 61 recruiting.
Jonsson Comprehensive Cancer Center sponsors 321 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 164 completed. 13 of these trials are in Phase 3-4 (later-stage) and 206 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Carcinoma, with 10 trials.
Top-decile sponsor footprint
Jonsson Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
164 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
321 total, page 1 of 7
RAD ONC FREEDOM Oncology Pain
NCT07605546
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
NCT07468903
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
NCT07323641
Virtual Reality vs. Music Relaxation for Reducing Anxiety and Pain During Breast Biopsies
NCT07310004
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
NCT07293585
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
NCT07150715
Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
NCT07235280
Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial
NCT07276438
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
NCT07164027
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
NCT07461948
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
NCT06934239
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
NCT07185165
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
NCT07339085
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT07118176
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
NCT06543576
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
NCT07089641
Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity
NCT07077239
Ivonescimab for the Treatment of Thymic Cancer
NCT06980077
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
NCT06995053
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT06810778
A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers
NCT06568016
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
NCT06788938
Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer
NCT06225011
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
NCT06432036
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
NCT06650163
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
NCT06572423
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
NCT06447103
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
NCT06216249
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
NCT06288113
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
NCT06538337
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
NCT06113016
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
NCT05775471
Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)
NCT06436612
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
NCT05398302
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
NCT06067269
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
NCT06064682
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
NCT06376565
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
NCT06059690
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
NCT05978128
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT05595499
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT05688215
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
NCT05256641
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
NCT05558904
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
NCT06090903
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT05319873
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
NCT04945642
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
NCT04712851
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
NCT04915508
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
NCT04857502
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
NCT04765150
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 100 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Jonsson Comprehensive Cancer Center pipeline
61 recruiting of 321 indexed (19% open); 164 completed (51%).
Phase mix: 13 late (III/IV) vs 206 early (I/II) (early-phase heavy).
Top condition: Prostate Carcinoma (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jonsson Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 321 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 321 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Allergan · 314 trials · 0% recruiting
- Genentech · 332 trials · 7% recruiting
Sponsors near 19% open enrollment (± trial volume)
- MemorialCare Health System · 19% recruiting · 21 trials
- University of North Texas Health Science Center · 19% recruiting · 21 trials
- University of Wisconsin, Milwaukee · 19% recruiting · 21 trials
- Verastem · 19% recruiting · 21 trials
Related
What to do with this Jonsson Comprehensive Cancer Center page
321 registered trials is a research-attention snapshot, not an endorsement of Jonsson Comprehensive Cancer Center or any single study.
- 61 of Jonsson Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Carcinoma is the condition Jonsson Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Jonsson Comprehensive Cancer Center pipeline card: 321 registered trials from official public datasets.Report a data error.